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Introduction 
The respiratory muscle strength of more than 2000 
subjects was measured as long ago as the mid 19th 
century by John Hutchinson. In 1846, his results of 
maximum respiratory pressures in 1061 healthy 
and 53 ‘diseased’ (i.e. tubercular) individuals were 
reported to the Medico-Chirurgical Society (1). The 
subjects were required to perform forceful inspiratory 
and expiratory efforts against a column of mercury 
via a connection to the nostrils and Hutchinson 
showed that certain groups of individuals developed 
greater pressures than others, depending on their 
state of health and fitness. Thus, of 14 ‘classes’ or 
occupations, pugilists and draymen generally per- 
formed best, while ‘paupers’ and the ‘diseased’ were 
only able to generate much lower pressures. Gentle- 
men also were noted ‘to stand very low in power’, a 
‘tolerably good gentleman’ being able ‘to raise 2.5 
inches of mercury (86 cmH,O) by the true inspiratory 
effort’. 
Like spirometry, which Hutchinson also intro- 
duced into clinical practice, such measurements had 
no significant impact for more than 100 yr. The 
modern era of measurement of maximum expiratory 
(PEmax) and inspiratory (Plmax) pressures dates 
from studies in healthy young adults by Ringqvist (2) 
and Black and Hyatt (3), and it is only in the last 
20 yr that such measurements have been commonly 
applied in clinical assessment. Initially the measure- 
ments were laboratory-based but they are now 
increasingly used in hospital wards, including inten- 
sive care units and in outpatients. Their wider appli- 
cability has been aided by the development of simple 
portable devices using microchip technology (4) 
(Plate 1). 
Clinical Physiology 
Systematic measurement of maximum pressures 
at different lung volumes shows that the greatest 
expiratory pressures are obtained with efforts 
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initiated at full inflation* while the most negative 
inspiratory pressures are recorded at low lung vol- 
umes (5). The relations between the pressure recorded 
and the lung volume at which it is generated corre- 
spond to the predicted consequences of the length- 
tension properties of skeletal muscle, since at total 
lung capacity (TLC) the expiratory muscles are at 
their greatest (i.e. optimal) length, while the inspira- 
tory muscles are at their optimal length at much 
smaller lung volumes. 
Maximum static respiratory pressures are 
measured at the mouth during forceful efforts against 
a closed or virtually closed airway. Provided that the 
glottis is open, the mouth pressure in this situation is 
equal to alveolar pressure. It includes a contribution 
(minor in healthy subjects) from the passive recoil of 
the respiratory systemt. Hence, mouth (or alveolar) 
pressure can only be exactly equated with muscle 
pressure if the respiratory system recoil is zero, 
a situation which applies at functional residual 
capacity (FRC), at least in healthy subjects. By 
convention, however, PEmax is usually measured 
with an expiratory effort initiated at TLC and there- 
fore includes a small contribution from passive recoil. 
Most normal data for PImax are based on efforts 
initiated at residual volume (RV), but in practice the 
values recorded are close to those obtained at FRC. 
Maximum static pressures assess global inspiratory 
and expiratory muscle function, i.e. the net effects 
of combined agonist and antagonist contraction. 
During inspiratory efforts, the agonists include the 
diaphragm, inspiratory intercostals, scalenes and 
accessory muscles such as sternomastoid. The major 
expiratory muscles are those of the abdominal wall, 
with the expiratory intercostals and other muscles 
*A forceful expiratory effort inevitably compresses the intrathoracic 
gas (Boyle’s Law) so that the thoracic volume at which the pressure 
is recorded is rather less than TLC. 
TThe alveolar (mouth) pressure is simply the algebraic sum of the 
respiratory system recoil pressure and the net pressure generated by 
respiratory muscle contraction. 
0 1995 W. B. Saunders Company Ltd 
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Plate I Two examples of portable devices for measuring maximum respiratory pressures. 
playing a lesser role. The mechanical contribution 
of the diaphragm alone can be assessed by direct 
measurement of transdiaphragmatic pressure using 
balloon catheters or other devices in the oesophagus 
and stomach, but the strength of other individual 
inspiratory and expiratory muscles cannot be 
measured in isolation. Some individuals find PZmax 
difficult to perform reproducibly; in these patients, 
measurement of oesophageal (pleural) pressure dur- 
ing a forceful sniff manoeuvre may be a useful 
alternative (6) but is clearly invasive. The pressure 
can be recorded more simply by passing a catheter 
through a plug inserted into one nostril while the 
subject sniffs forcefully through the other nostril (7), 
but, in patients, with severe pulmonary or airway 
disease, this will not faithfully reflect alveolar 
pressure. 
Practical Aspects of Measurement 
By their very nature, measurements of maximum 
static pressure are effort-dependent and consequently 
there may sometimes be uncertainty as to the validity 
of the values recorded. Good reproducibility is often 
taken as a guide to validity, but it has recently been 
pointed out that this may not necessarily be the case 
(8). Some subjects find the associated sensation 
unpleasant and care needs to be taken to avoid 
recording pressures generated only by the buccal 
muscles with the glottis closed - this can be achieved 
by introducing a small leak in the mouthpiece. The 
measurements are also importantly influenced by the 
type of mouthpiece used- in strongly motivated 
young subjects, the tube type of mouthpiece used in 
the classic study by Black and Hyatt (3) gives the 
greatest values, particularly when the hands are 
used to keep the tube pressed against the lips. A 
conventional flanged mouthpiece is often much easier 
for patients to use but consistently gives lower values 
(9) (Table 1). Several series of reference values are 
available but the normal ranges are wide and for this 
test more than most, it is essential to compare the 
values obtained with those measured in healthy 
individuals using similar techniques in the same 
laboratory. 
Usually, the pressure recorded is the largest 
numerical value which can be sustained for at least 
1 s. Strictly, according to the standard convention, 
inspiratory pressures are negative (with respect to 
atmospheric) so that minimum inspiratory pressure 
would be more correct. In practice, however, the 
maximum inspiratory pressure with numerically 
positive values is usually reported. In healthy sub- 
jects, PEmax is numerically greater than PZmax. An 
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Table 1 Reference values for maximum respiratory pressures 
Effect of mouthpiece design 
Reference No. PEmax PImax 
(male) cmH,O mean f SD 
Ringqvist (2) 106 238 f 46 129*32 
Black and Hyatt (3) 60 232 f 42 123 f 21 
Rochester and Arora (10) 80 216 f 45 126+28 
Leech et al. (11) 325 154f82 113+36 
Wilson et al. (12) 80 148 f 34 106 f 31 
Vincken et al. (13) 46 140 f 38 105 + 25 
Mouthpiece 
Tube 
Tube 
Tube 
Flanged 
Flanged 
Flanged 
Source: Koulouris et al. 1988 (9). 
overall assessment can be obtained by calculating the In the more common situation of unilateral 
arithmetic mean of the two values giving an index diaphragmatic paralysis, the results are intermediate 
which is sometimes called ‘respiratory muscle with PZmax in the low normal range or mildly 
strength’ (RMS) (14). reduced (56). 
Clinical Relevance 
The range of conditions in which respiratory 
muscle weakness may occur and in which reductions 
of maximum respiratory pressures have been 
reported is extremely wide. In some instances, specific 
metabolic, degenerative or inflammatory changes are 
responsible, while in others, respiratory muscle 
weakness accompanies generalized malnutrition and 
muscle wasting. Some of the most common associ- 
ations are listed in Table 2. Some, such as the specific 
disorders of muscle, are self-evident while other 
associations are less obvious and in some cases the 
precise mechanisms are obscure. In the primary 
muscle dystrophies and myopathies, respiratory 
muscle weakness is usually proportional to the weak- 
ness of muscles elsewhere, while occasionally (e.g. 
acid maltase deficiency), the diaphragm appears to be 
more specifically affected and, consequently, PImax 
may be disproportionately reduced. In many other 
situations, however, PEmax is proportionally more 
reduced than PImax but it is not clear whether this 
truly represents a greater relative reduction of ex- 
piratory muscle force (as opposed to pressure) or 
whether (and perhaps more likely), it merely reflects 
an alinear relation between the force generated and 
the pressure measured. 
Respiratory muscle function depends ultimately on 
an adequate supply of oxygen and substrates to the 
contracting muscle. Therefore, compromised muscle 
function would be expected in the presence of 
severely impaired cardiac output and/or hypoxaemia. 
Numerous metabolic and endocrine factors are 
important for maintaining skeletal muscle function 
and these are increasingly recognized as important 
causes of respiratory muscle weakness. In addition to 
the conditions listed in Table 2, it is likely that other 
specific deficiencies or metabolic disturbances have 
similar effects, but no systematic studies are available 
to date. Examples would include vitamin D defi- 
ciency, glycogen storage diseases, periodic paralysis 
and hypokalaemia. 
In the rare situation of bilateral diaphragmatic 
paralysis with otherwise normal respiratory muscle 
function (e.g. occasionally in neuralgic amyotrophy 
or after coronary artery bypass grafting), PEmax 
is normal while the remaining inspiratory muscles 
are capable of generating values of PImax which 
are approximately one-half of the normal value, (55). 
In undernourished and cachectic patients, severe 
respiratory muscle weakness is common (32) and this 
is likely to apply to many patients with advanced 
malignancy and other debilitating diseases [such as 
those with tuberculosis studied by Hutchinson (l)]. 
Among endocrine conditions, respiratory muscle 
weakness appears to be particularly common in both 
hyper- and hypothyroidism. Adrenal disease has been 
studied less extensively - muscle weakness would be 
expected in Addison’s disease, a conclusion sup- 
ported by one case report (38). In Cushing’s syn- 
drome, one preliminary report surprisingly showed 
no significant respiratory muscle weakness, (57) but 
there is increasing awareness of reduced maximum 
respiratory pressures in patients with iatrogenic 
Cushing’s syndrome (40,41). Again, in diabetes mel- 
litus, the situation is unclear as one study (39) of 
otherwise healthy subjects showed mildly impaired 
PZmax while another study showed no difference 
from control values (58). 
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Table 2 Conditions associated with impaired respiratory muscle strength 
Condition References 
C.N.S. 
Peripheral neuropathy 
Myasthenic disorders 
Muscular dystrophies 
Nutritional deficiencies 
Endocrine conditions 
Toxic myopathies 
Collagen diseases 
Miscellaneous 
Respiratory diseases 
Parkinson’s disease 
Quadriplegia 
Multiple sclerosis 
Poliomyelitis (‘post polio syndrome’) 
Motor neurone disease 
Guillain-Barre syndrome 
Hereditary motor and sensory neuropathy 
(Charcot-Marie-Tooth) 
Myasthenia gravis 
Lambert-Eaton syndrome 
Duchenne dystrophy 
Limb girdle dystrophy 
Myotonic dystrophy 
General malnutrition 
Hypomagnesaemia 
Hyperthyroidism 
Hypothyroidism 
Addison’s disease 
Diabetes mellitus 
Alcoholic myopathy 
Steroid myopathy 
Systemic lupus erythematosus 
Polymyositis/dermatomyositis 
Systemic sclerosis 
Rheumatoid arthritis 
Chronic cardiac failure 
Chronic renal failure 
Viral URTI 
Fibrosing alveolitis 
COPD 
15,16 
17 
18,19 
20,21 
22.23 
24 
2526 
27 
28 
29,30 
31 
22 
32,33 
34 
35,36 
37 
38 
39 
14 
40,41 
42,43 
14 
44 
45 
46,47 
48,49 
50 
51,52 
53,54 
URTI, upper respiratory tract infection; COPD, chronic obstructive pulmonary disease. 
Respiratory muscle weakness appears to be 
common in the collagen diseases, although the 
mechanisms are uncertain in many cases and steroid 
treatment may contribute in some. Moderate reduc- 
tions of maximum pressures are common in systemic 
lupus erythematosus (SLE), especially in patients 
with the ‘shrinking lung’ syndrome, (42), whereas in 
systemic sclerosis it appears that alveolar fibrosis and 
pulmonary vascular disease are more likely respir- 
atory associations. In rheumatoid arthritis, an 
impaired PImax has been shown to be inversely 
related to the duration of treatment with steroids, 
(43, but it is uncertain whether this implies cause 
and effect or, alternatively, whether the duration 
of steroid therapy merely reflects more severe and 
prolonged rheumatoid disease. 
In cardiac disease, weakness of the respiratory 
muscles has been shown to contribute to the 
reduction of lung volumes of some patients with 
mitral valve disease (59). However, in patients 
with advanced chronic left ventricular failure, 
reductions in PEmax and PZmax appear to be com- 
mon and inspiratory muscle strength correlates with 
the severity of dyspnoea during daily activities (60). 
The situation in primary respiratory disease 
deserves special mention. In fibrotic lung disease, 
typically cryptogenic fibrosing alveolitis, mild to 
moderate reductions of maximum pressures have 
been reported (51,52), which, in some individuals, 
may be due to steroid treatment. In patients with 
chronic airway obstruction (COPD), the situation is 
complicated by the accompanying hyperinflation. 
This particularly affects values of PZmax which are 
inevitably measured at a much larger absolute vol- 
ume (whether RV or FRC) than in healthy subjects. 
For this reason alone, values of PZmax would be 
expected to be numerically smaller than normal since 
the mechanical advantage of the inspiratory muscles 
will be reduced at the greater thoracic volume. In 
addition, many patients with advanced COPD 
develop generalized muscle weakness. Unlike the 
inspiratory muscles, the expiratory muscles are not at 
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a mechanical disadvantage in the presence of an 
increased thoracic volume. Consequently, Rochester 
and Braun (54) argued that PEmax can be used as 
an index of respiratory muscle strength in such 
patients in order to analyse the respective contri- 
butions of weakness and mechanical disadvantage 
to the impairment of PZmax. Their calculations 
showed that, overall, both factors made similar con- 
tributions, with the proportion varying in different 
individuals. 
Practical Applications 
Respiratory muscle weakness is frequently unsus- 
pected before measurements of maximum pressures 
are made. The results are easiest to interpret when the 
values obtained are normal or when they are clearly 
markedly impaired and reproducible. Therefore in 
practice, these measurements often play a role in 
excluding significant respiratory muscle weakness. If 
intermediate, equivocal or inconsistent results are 
obtained, further investigation is indicated. This 
might, for example, include more invasive or more 
specialized tests such as measurement of transdia- 
phragmatic pressure or of phrenic nerve conduction. 
The most common clinical applications of 
measurement of maximum respiratory pressures are 
discussed below. 
IN DIAGNOSIS 
Measurement of maximum respiratory pressures is 
particularly relevant to the patient who presents with 
otherwise unexplained dyspnoea or with a restrictive 
ventilatory defect with no apparent cause radio- 
graphically. Theoretical considerations suggest that 
in mild or moderate respiratory muscle weakness, 
measurements of maximum pressures should be more 
sensitive than the vital capacity, but this is not always 
borne out in practice because of the wide normal 
range and the less good signal:noise ratio of the 
former measurements. Patients with previously 
unrecognized respiratory muscle weakness may also 
occasionally present with hypercapnic respiratory 
failure for no obvious reason, or with difficulty in 
weaning from ventilation following general anaes- 
thesia. In such situations, respiratory muscle weak- 
ness is usually severe and measurement of maximum 
pressures is diagnostic. 
ASSESSING THE CONTRIBUTION OF RESPIRATORY 
MUSCLE WEAKNESS TO SYMPTOMS IN 
ESTABLISHED DISEASES 
As it is so common, respiratory muscle weakness 
may contribute to the symptoms of patients with 
various respiratory and non-respiratory diseases. 
Common examples include those with COPD, par- 
ticularly in the face of weight loss and malnutrition, 
patients with endocrine and collagen diseases and 
those on long-term treatment with corticosteroids for 
any reason. 
ASSESSMENT OF SEVERITY 
Measurement of maximum respiratory pressures is 
especially relevant to patients with neuromuscular 
diseases where the severity of respiratory muscle 
weakness is easily underestimated, particularly when 
the patient’s mobility is reduced because of general- 
ized weakness. Hypercapnia in patients with respir- 
atory muscle weakness implies very severe disease 
with RMS reduced to one-third or so of predicted 
values, although weakness may interact with coexist- 
ing chronic airway disease to result in hypercapnia 
with less severe weakness (14). 
FOLLOWING PROGRESS AND RESPONSE TO TREATMENT 
Measurement of maximum respiratory pressures is 
most relevant over the short to medium term in 
progressive or fluctuating conditions such as poly- 
myositis, myasthenia gravis and Guillain-Barre 
syndrome, where measurements of both maximum 
pressures and vital capacity should be obtained at 
appropriate intervals. 
Conclusions 
Measurements of maximum respiratory pressures 
are now readily available and easy to apply. Their 
value is limited by their dependence on effort and 
on the system used, as well as the wide range of 
normality. As with all tests of respiratory function, 
the values obtained should be interpreted in the 
light of other clinical and functional information. 
Maximum pressures are of most value in excluding 
significant respiratory muscle weakness and in 
following the progress of patients with established 
weakness. In practice, PZmax numerically 
>SOcmH,O (8 kPa) or PEmax > 100 cmH,O 
(10 kPa) excludes clinically sig@cant inspiratory or 
expiratory muscle weakness. Lower values in the 
appropriate clinical setting should be an indication 
for further investigation. 
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